{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:30:48Z","timestamp":1788514248796,"version":"build-2803163510"},"reference-count":27,"publisher":"American Diabetes Association","issue":"11","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>This study investigated the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>In this pilot, multicenter, open-label, randomized study, patients (n = 90) with a known history of T2D treated with diet, oral antidiabetic agents, or low total daily dose of insulin (\u22640.4 units\/kg\/day) were randomized to receive sitagliptin alone or in combination with glargine insulin (glargine) or to a basal bolus insulin regimen (glargine and lispro) plus supplemental (correction) doses of lispro. Major study outcomes included differences in daily blood glucose (BG), frequency of treatment failures (defined as three or more consecutive BG &amp;gt;240 mg\/dL or a mean daily BG &amp;gt;240 mg\/dL), and hypoglycemia between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Glycemic control improved similarly in all treatment groups. There were no differences in the mean daily BG after the 1st day of treatment (P = 0.23), number of readings within a BG target of 70 and 140 mg\/dL (P = 0.53), number of BG readings &amp;gt;200 mg\/dL (P = 0.23), and number of treatment failures (P &amp;gt; 0.99). The total daily insulin dose and number of insulin injections were significantly less in the sitagliptin groups compared with the basal bolus group (both P &amp;lt; 0.001). There were no differences in length of hospital stay (P = 0.78) or in the number of hypoglycemic events between groups (P = 0.86).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Results of this pilot indicate that treatment with sitagliptin alone or in combination with basal insulin is safe and effective for the management of hyperglycemia in general medicine and surgery patients with T2D.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc13-0277","type":"journal-article","created":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T04:15:05Z","timestamp":1374552905000},"page":"3430-3435","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":150,"title":["Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes"],"prefix":"10.2337","volume":"36","author":[{"given":"Guillermo E.","family":"Umpierrez","sequence":"first","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma","family":"Gianchandani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Smiley","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Wesorick","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Newton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnoosh","family":"Farrokhi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Peng","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Lathkar-Pradhan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Health System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pasquel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"2022031302065914300_B1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2337\/diacare.27.2.553","article-title":"Management of diabetes and hyperglycemia in hospitals","volume":"27","author":"Clement","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jcem.87.3.8341","article-title":"Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes","volume":"87","author":"Umpierrez","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031302065914300_B3","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1056\/NEJMcp060094","article-title":"Clinical practice. Management of hyperglycemia in the hospital setting","volume":"355","author":"Inzucchi","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031302065914300_B4","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2337\/dc10-0304","article-title":"Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery","volume":"33","author":"Frisch","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/014860719802200277","article-title":"Early postoperative glucose control predicts nosocomial infection rate in diabetic patients","volume":"22","author":"Pomposelli","year":"1998","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2022031302065914300_B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/eje.1.02321","article-title":"Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery","volume":"156","author":"Noordzij","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2022031302065914300_B7","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jhm.356","article-title":"Society of Hospital Medicine Glycemic Control Task Force summary: practical recommendations for assessing the impact of glycemic control efforts","volume":"3","author":"Schnipper","year":"2008","journal-title":"J Hosp Med"},{"key":"2022031302065914300_B9","first-page":"65","article-title":"Position statement: inpatient glycemic control","volume":"35","author":"Seley","year":"2009","journal-title":"Diabetes Educ"},{"key":"2022031302065914300_B10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031302065914300_B11","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/dc07-0295","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1210\/jc.2008-1441","article-title":"Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes","volume":"94","author":"Umpierrez","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031302065914300_B13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2337\/dc08-1436","article-title":"Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial","volume":"32","author":"Korytkowski","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/dc10-1407","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)","volume":"34","author":"Umpierrez","year":"2011","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2337\/dc06-1715","article-title":"Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals","volume":"30","author":"Wexler","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B16","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.amjmed.2011.07.011","article-title":"Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities","volume":"124","author":"Boucai","year":"2011","journal-title":"Am J Med"},{"key":"2022031302065914300_B17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0735-1097(98)00038-2","article-title":"The sulfonylurea controversy: more questions from the heart","volume":"31","author":"Brady","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2022031302065914300_B18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"2022031302065914300_B20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022031302065914300_B21","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2337\/dc07-0627","article-title":"Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes","volume":"30","author":"Goldstein","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1185\/030079907X188152","article-title":"Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes","volume":"23","author":"Hanefeld","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2022031302065914300_B23","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s00125-006-0416-z","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus","volume":"49","author":"Raz","year":"2006","journal-title":"Diabetologia"},{"key":"2022031302065914300_B24","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2337\/dc06-9916","article-title":"Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association","volume":"29","author":"Kitabchi","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B25","doi-asserted-by":"crossref","DOI":"10.2337\/dc12-1988","article-title":"Randomized study comparing a basal bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal Plus Trial","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031302065914300_B26","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1097\/01.CCM.0000282073.98414.4B","article-title":"Severe hypoglycemia in critically ill patients: risk factors and outcomes","volume":"35","author":"Krinsley","year":"2007","journal-title":"Crit Care Med"},{"key":"2022031302065914300_B27","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2337\/dc08-2127","article-title":"Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward","volume":"32","author":"Turchin","year":"2009","journal-title":"Diabetes Care"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/11\/3430\/615441\/3430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/11\/3430\/615441\/3430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:15:00Z","timestamp":1647152100000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/11\/3430\/38080\/Safety-and-Efficacy-of-Sitagliptin-Therapy-for-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,10,15]]},"published-print":{"date-parts":[[2013,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc13-0277","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,15]]}}}